Lungpacer Medical Announces Investigational Device Exemption (IDE) for STARI, Phase 2 Feasibility Clinical Trial Lungpacer Medical is excited to announce approval of an Investigational Device Exemption (IDE) from the U.S. FDA for the STARI clinical study.

Lungpacer Medical Announces Positive Results from STIMULUS Trial: Diaphragm Neurostimulation Improves Hemodynamic Performance During Mechanical Ventilation Lungpacer Medical Announces Positive Results from STIMULUS Trial: Diaphragm Neurostimulation Improves Hemodynamic Performance During Mechanical Ventilation

Lungpacer Medical Announces Premarket Approval for AeroPace® System EXTON, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Lungpacer Medical, a neurostimulation company dedicated to developing innovative interventional therapies to free patients from mechanical ventilation...

Lungpacer Medical Announces PMA Submission for AeroPace® System Lungpacer Medical today announced that its AeroPace System is under Food and Drug Administration (FDA) review in a premarket approval (PMA) application.

Lungpacer Medical Accelerates Pivotal Clinical Study with AeroPace™ System EXTON, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace™ System, a next generation product,...